There were some people who were giving it only a 50-50 chance [Pfizer] would win. We thought it was a big probability that they'd win. It's not a surprise the stock is moving up. A lot of value investors were on the sidelines, because they just don't buy things that have a huge risk in front of them. |
These drugs all work in one mechanism. If someone came out with a different type of erectile dysfunction drug there might be potential to expand the ED market, but these three drugs essentially do the same thing. |
They both could be key products. |
We think it might make sense for them to try and focus on what they do well, which is Phase III testing and marketing, |
We've seen [generic challengers'] success rate go down dramatically over last year. The drug companies are getting more experienced at defending these challenges. |
You just can't grow the top line. I view Pfizer as a duck. They're floating and it looks easy, but they're paddling like crazy underneath. |